FIELD: biology, medicine, biochemistry. SUBSTANCE: fused protein no occurring in nature and containing elongating peptide fragment covalently bound by its C-end with N-end of protein central part of the general formula (I): A-X-Y-(X1-Y)n-protein where A - H, Met and if A - H then protein is an analog of bGRF; if A - Met then protein is HIV-RNAase-4; X - Ala, Ser, Tyr, Val, Arg, Gly, Lys, Pro, Phe; Y - Ala, Ser, Thr, Pro; X′ - Ala, Gly, Ile, His, Lys, Phe, Tyr; n = 0-4; if n = 0 and A - H, Y - Ala, Ser, Thr. Method of isolation of fused protein of the formula (I) where A - Met; n = 4; X - Ala, Gly, Pro; Y - Ala, Pro; X′ - His; "protein" - HIV-RNAase involves column chromatography on Sepharose Pharmacia containing immobilized metal ions. Fused protein can be used for construction of drugs showing the prolonged effect. EFFECT: improved method of isolation. 9 cl, 6 tbl
Title | Year | Author | Number |
---|---|---|---|
PEPTIDE DERIVATIVES - ANALOGS OF GRF OR THEIR NONTOXIC SALTS | 1990 |
|
RU2096416C1 |
FUSED PROTEIN CONSTRUCTS FOR COMPLEMENT-RELATED DISEASE | 2019 |
|
RU2824402C2 |
FGF21 FUSED WITH LONG-ACTING PROTEINS AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | 2016 |
|
RU2741087C2 |
GLYCOSYLATED FUSED PROTEINS VWF WITH IMPROVED PHARMACOKINETICS | 2017 |
|
RU2782212C2 |
BINDING OF FUSED PROTEIN TO CD47 PROTEIN AND ITS USE | 2019 |
|
RU2787521C2 |
NEW MODIFIED IMMUNOGLOBULIN Fc-FRAGMENT FUNCTION PROTEIN AND ITS USE | 2020 |
|
RU2800919C2 |
POLYVALENT AND POLYSPECIFIC GITR-BINDING FUSED PROTEINS | 2016 |
|
RU2753439C2 |
IMMUNOGENIC FUSED PROTEIN | 2016 |
|
RU2757426C2 |
FUSION PROTEIN | 2016 |
|
RU2748643C2 |
POLYVALENT AND POLYSPECIFIC OX40-BINDING FUSED PROTEINS | 2017 |
|
RU2773052C2 |
Authors
Dates
1998-06-27—Published
1993-06-11—Filed